Program
RSVt Vaccine
Also written as “Low Dose (LD) RSVt vaccine”, “Standard Dose (SD) RSVt vaccine” and “High Dose (HD) RSVt vaccine”.
Its studies are mostly in Respiratory Syncytial Virus Infections, led by Sanofi.
Furthest: phase 3, since Jan 24, 20243 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 30 open or running | phase 3since Jan 24, 2024 | Jan 6, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 6, 2023First study: phase 2 study in Respiratory Syncytial Virus InfectionsFirst studyNCT05687279 · 80 enrolled · United States, Puerto Rico
- Jan 24, 2024Phase 3 study in RSV ImmunisationNCT06252285 · 6,300 enrolled · United States, Argentina, Brazil and more
- Nov 22, 2024Phase 3 study in RSV ImmunisationNCT06705140 · 42 enrolled · Honduras
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“RSVt Vaccine”name, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06705140RSV Immunisation · Honduras | 3 | Terminated | Jun 11, 2025 | 42 |
| NCT06252285RSV Immunisation · United States, Argentina, Brazil and more | 3 | Terminated | Dec 4, 2025 | 6,300 |
| NCT05687279Respiratory Syncytial Virus Infections · United States, Puerto Rico | 2 | Completed | Dec 27, 2024 | 80 |
How it is read
Names in the registry
- “RSVt Vaccine”, 2 entries
- “Low Dose (LD) RSVt vaccine”, 1 entry
- “Standard Dose (SD) RSVt vaccine”, 1 entry
- “High Dose (HD) RSVt vaccine”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.